Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Emergent BioSolutions price target lowered to $15 from $25 at TD Cowen » 07:24
05/19/23
05/19
07:24
05/19/23
07:24
EBS

Emergent BioSolutions

$8.64 /

-0.4 (-4.43%)

TD Cowen lowered the…

TD Cowen lowered the firm's price target on Emergent BioSolutions to $15 from $25 and keeps a Market Perform rating on the shares. The analyst said they reached an amended credit facility agreement with their lenders pushing the repayment date back to May 15 2025. We view the agreement as a positive for the company now but a covenant focused on EBITDA will keep strong focus on financial performance.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$8.64 /

-0.4 (-4.43%)

EBS Emergent BioSolutions
$8.64 /

-0.4 (-4.43%)

04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy at Benchmark after Narcan OTC approval
04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy from Hold at Benchmark
03/17/23 JPMorgan
Emergent BioSolutions downgraded to Underweight from Neutral at JPMorgan
12/28/22 Benchmark
Benchmark keeps Hold on Emergent after non-profit OTC naloxone competitor news
EBS Emergent BioSolutions
$8.64 /

-0.4 (-4.43%)

EBS Emergent BioSolutions
$8.64 /

-0.4 (-4.43%)

Hot Stocks
Emergent BioSolutions sells travel health business to Bavarian Nordic » 07:59
05/15/23
05/15
07:59
05/15/23
07:59
EBS

Emergent BioSolutions

$9.17 /

-1.335 (-12.71%)

, BVNRY

Bavarian Nordic

$10.07 /

-0.05 (-0.49%)

Emergent BioSolutions…

Emergent BioSolutions (EBS) announced it has completed the sale of its travel health business to Bavarian Nordic (BVNRY). At closing Emergent received $270 million, subject to customary closing adjustments, and may receive up to an additional $110 million in potential future milestone payments. With the transaction closed, Bavarian Nordic has acquired the rights to Vivotif, the licensed typhoid vaccine, and Vaxchora, the licensed cholera vaccine, as well as the development-stage chikungunya vaccine candidate CHIKV VLP. Bavarian Nordic also acquired manufacturing facilities in Bern, Switzerland, and development facilities in San Diego, California. The majority of Emergent employees supporting these products and facilities are joining Bavarian Nordic.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$9.17 /

-1.335 (-12.71%)

BVNRY Bavarian Nordic
$10.07 /

-0.05 (-0.49%)

EBS Emergent BioSolutions
$9.17 /

-1.335 (-12.71%)

04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy at Benchmark after Narcan OTC approval
04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy from Hold at Benchmark
03/17/23 JPMorgan
Emergent BioSolutions downgraded to Underweight from Neutral at JPMorgan
12/28/22 Benchmark
Benchmark keeps Hold on Emergent after non-profit OTC naloxone competitor news
BVNRY Bavarian Nordic
$10.07 /

-0.05 (-0.49%)

07/20/22 TD Cowen
Bavarian Nordic upgraded to Outperform from Market Perform at Cowen
EBS Emergent BioSolutions
$9.17 /

-1.335 (-12.71%)

BVNRY Bavarian Nordic
$10.07 /

-0.05 (-0.49%)

EBS Emergent BioSolutions
$9.17 /

-1.335 (-12.71%)

Hot Stocks
Emergent BioSolutions falls -14.7% » 12:00
05/12/23
05/12
12:00
05/12/23
12:00
EBS

Emergent BioSolutions

$8.95 /

-1.555 (-14.80%)

Emergent BioSolutions is…

Emergent BioSolutions is down -14.7%, or -$1.55 to $8.96.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$8.95 /

-1.555 (-14.80%)

EBS Emergent BioSolutions
$8.95 /

-1.555 (-14.80%)

04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy at Benchmark after Narcan OTC approval
04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy from Hold at Benchmark
03/17/23 JPMorgan
Emergent BioSolutions downgraded to Underweight from Neutral at JPMorgan
12/28/22 Benchmark
Benchmark keeps Hold on Emergent after non-profit OTC naloxone competitor news
EBS Emergent BioSolutions
$8.95 /

-1.555 (-14.80%)

EBS Emergent BioSolutions
$8.95 /

-1.555 (-14.80%)

Earnings
Emergent BioSolutions sees FY23 revenue $1.1B-$1.2B, consensus $1.13B » 16:48
05/09/23
05/09
16:48
05/09/23
16:48
EBS

Emergent BioSolutions

$9.71 /

+0.595 (+6.53%)

Raises FY23 adjusted…

Raises FY23 adjusted EBITDA view to $100M-$150M from $75M-$125M

ShowHide Related Items >><<
EBS Emergent BioSolutions
$9.71 /

+0.595 (+6.53%)

EBS Emergent BioSolutions
$9.71 /

+0.595 (+6.53%)

04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy at Benchmark after Narcan OTC approval
04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy from Hold at Benchmark
03/17/23 JPMorgan
Emergent BioSolutions downgraded to Underweight from Neutral at JPMorgan
12/28/22 Benchmark
Benchmark keeps Hold on Emergent after non-profit OTC naloxone competitor news
EBS Emergent BioSolutions
$9.71 /

+0.595 (+6.53%)

EBS Emergent BioSolutions
$9.71 /

+0.595 (+6.53%)

Earnings
Emergent BioSolutions sees Q2 revenue $210M-$230M, consensus $222.48M  16:48
05/09/23
05/09
16:48
05/09/23
16:48
EBS

Emergent BioSolutions

$9.71 /

+0.595 (+6.53%)

 
ShowHide Related Items >><<
EBS Emergent BioSolutions
$9.71 /

+0.595 (+6.53%)

EBS Emergent BioSolutions
$9.71 /

+0.595 (+6.53%)

04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy at Benchmark after Narcan OTC approval
04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy from Hold at Benchmark
03/17/23 JPMorgan
Emergent BioSolutions downgraded to Underweight from Neutral at JPMorgan
12/28/22 Benchmark
Benchmark keeps Hold on Emergent after non-profit OTC naloxone competitor news
EBS Emergent BioSolutions
$9.71 /

+0.595 (+6.53%)

EBS Emergent BioSolutions
$9.71 /

+0.595 (+6.53%)

Earnings
Emergent BioSolutions reports Q1 adjusted EPS ($3.17), consensus ($1.24) » 16:17
05/09/23
05/09
16:17
05/09/23
16:17
EBS

Emergent BioSolutions

$9.71 /

+0.595 (+6.53%)

Reports Q1 revenue…

Reports Q1 revenue $165.1M, consensus $143.28M. "Since the beginning of the year, we have taken strategic actions to stabilize and strengthen our core businesses to create sustainable, long-term value for all our stakeholders," said Robert G. Kramer, president and CEO of Emergent BioSolutions. "The impending sale of our travel health business, notices of intent from the U.S. government to procure medical countermeasures, productive conversations with our lenders, and the anticipated launch of over-the-counter Narcan(R) Nasal Spray later this summer all help build momentum for the rest of 2023 and beyond."

ShowHide Related Items >><<
EBS Emergent BioSolutions
$9.71 /

+0.595 (+6.53%)

EBS Emergent BioSolutions
$9.71 /

+0.595 (+6.53%)

04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy at Benchmark after Narcan OTC approval
04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy from Hold at Benchmark
03/17/23 JPMorgan
Emergent BioSolutions downgraded to Underweight from Neutral at JPMorgan
12/28/22 Benchmark
Benchmark keeps Hold on Emergent after non-profit OTC naloxone competitor news
EBS Emergent BioSolutions
$9.71 /

+0.595 (+6.53%)

EBS Emergent BioSolutions
$9.71 /

+0.595 (+6.53%)

Over a month ago
Hot Stocks
Emergent BioSolutions falls -4.1% » 09:47
04/24/23
04/24
09:47
04/24/23
09:47
EBS

Emergent BioSolutions

$9.98 /

-0.385 (-3.71%)

Emergent BioSolutions is…

Emergent BioSolutions is down -4.1%, or -42c to $9.95.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$9.98 /

-0.385 (-3.71%)

EBS Emergent BioSolutions
$9.98 /

-0.385 (-3.71%)

04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy at Benchmark after Narcan OTC approval
04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy from Hold at Benchmark
03/17/23 JPMorgan
Emergent BioSolutions downgraded to Underweight from Neutral at JPMorgan
12/28/22 Benchmark
Benchmark keeps Hold on Emergent after non-profit OTC naloxone competitor news
EBS Emergent BioSolutions
$9.98 /

-0.385 (-3.71%)

EBS Emergent BioSolutions
$9.98 /

-0.385 (-3.71%)

Hot Stocks
Emergent BioSolutions falls -6.9% » 12:00
04/18/23
04/18
12:00
04/18/23
12:00
EBS

Emergent BioSolutions

$10.87 /

-0.835 (-7.13%)

Emergent BioSolutions is…

Emergent BioSolutions is down -6.9%, or -81c to $10.90.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$10.87 /

-0.835 (-7.13%)

EBS Emergent BioSolutions
$10.87 /

-0.835 (-7.13%)

04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy at Benchmark after Narcan OTC approval
04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy from Hold at Benchmark
03/17/23 JPMorgan
Emergent BioSolutions downgraded to Underweight from Neutral at JPMorgan
12/28/22 Benchmark
Benchmark keeps Hold on Emergent after non-profit OTC naloxone competitor news
EBS Emergent BioSolutions
$10.87 /

-0.835 (-7.13%)

EBS Emergent BioSolutions
$10.87 /

-0.835 (-7.13%)

Hot Stocks
Emergent BioSolutions rises 13.4% » 12:00
04/10/23
04/10
12:00
04/10/23
12:00
EBS

Emergent BioSolutions

$11.98 /

+1.45 (+13.77%)

Emergent BioSolutions is…

Emergent BioSolutions is up 13.4%, or $1.42 to $11.98.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$11.98 /

+1.45 (+13.77%)

EBS Emergent BioSolutions
$11.98 /

+1.45 (+13.77%)

04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy at Benchmark after Narcan OTC approval
04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy from Hold at Benchmark
03/17/23 JPMorgan
Emergent BioSolutions downgraded to Underweight from Neutral at JPMorgan
12/28/22 Benchmark
Benchmark keeps Hold on Emergent after non-profit OTC naloxone competitor news
EBS Emergent BioSolutions
$11.98 /

+1.45 (+13.77%)

EBS Emergent BioSolutions
$11.98 /

+1.45 (+13.77%)

Hot Stocks
Emergent BioSolutions rises 9.8% » 10:00
04/10/23
04/10
10:00
04/10/23
10:00
EBS

Emergent BioSolutions

$11.57 /

+1.04 (+9.88%)

Emergent BioSolutions is…

Emergent BioSolutions is up 9.8%, or $1.04 to $11.60.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$11.57 /

+1.04 (+9.88%)

EBS Emergent BioSolutions
$11.57 /

+1.04 (+9.88%)

04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy at Benchmark after Narcan OTC approval
04/10/23 Benchmark
Emergent BioSolutions upgraded to Buy from Hold at Benchmark
03/17/23 JPMorgan
Emergent BioSolutions downgraded to Underweight from Neutral at JPMorgan
12/28/22 Benchmark
Benchmark keeps Hold on Emergent after non-profit OTC naloxone competitor news
EBS Emergent BioSolutions
$11.57 /

+1.04 (+9.88%)

EBS Emergent BioSolutions
$11.57 /

+1.04 (+9.88%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.